Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Appointments: Novartis And GSK Fill Key R&D Roles, Celgene Board Changes And Others

Executive Summary

This week's announcements include Novartis's replacement for Vas Narasimhan as head of global development, GlaxoSmithKline's new head of worldwide business development for pharmaceuticals research & development, new board members at Celgene, an interim CEO at Nordic Nanovector, and changes at Vectura, PureTech Health and Exicure.

You may also be interested in...



Pipeline Watch: 22 Approvals And 15 Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: New Roles Filled at Lisata Therapeutics, Roquefort Therapeutics and Voyager Therapeutics

This week's executive changes in the industry include new CEOs at Roquefort Therapeutics, Lisata Therapeutics and Everest Medicines, while Vyriad and RenovoRx get new chief operating officers. 

Publisher's Spotlight: Scrip Awards Announces 2022 Finalists

We are delighted to announce the shortlist for the 18th Annual Scrip Awards.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC122982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel